Software validates clinical data management software.
Share:
Press Release Summary:
Pharsight Knowledgebase Server v3.0 Validation Suite(TM) enables rapid and reliable validation of PKS 3.0 installations using combination of automated and manual tests. It provides templates for validation life cycle documents, such as Validation Plan, Test Plan, and Validation Summary Report, and inserts automated test results into Validation Run Report.
Original Press Release:
Pharsight Releases PKS® Validation Suite(TM)
New Offering Will Ease Upgrade and Validation of Pharsight(R) Knowledgebase Server(TM)
MOUNTAIN VIEW, Calif., Jan. 6 / -- Pharsight Corporation (BULLETIN BOARD: PHST) , a leading provider of software and strategic services designed to optimize clinical drug development, today announced that it has released Pharsight Knowledgebase Server (PKS) Validation Suite. The Validation Suite enables rapid and reliable validation of PKS 3.0 installations using a combination of automated and manual tests. The Validation Suite provides templates for validation life cycle documents, such as a Validation Plan, Test Plan, and Validation Summary Report, and inserts automated test results into a Validation Run Report.
"Computer systems validation is a crucial aspect of compliance and can be a rate-limiting step in the installation of clinical data management and analysis systems," said Shawn O'Connor, President and Chief Executive Officer of Pharsight. "The PKS Validation Suite streamlines the validation process for Pharsight's PKS product, resulting in a shorter path to the efficiencies and reliability advantages that PKS offers. The Validation Suite products, for both PKS and WinNonlin, are indicative of Pharsight's commitment to enabling the deployment of its products within the rigorously regulated clinical environment."
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers' development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at www.pharsight.com.
NOTE: Pharsight, Pharsight Knowledgebase Server, PKS, PKS Validation Suite, WinNonlin are trademarks or registered trademarks of Pharsight Corporation.
